Jeroen de Ridder

Jeroen de Ridder is a Full Professor at Utrecht University's Faculty of Medicine, leading the Bioinformatics in molecular medicine research group at University Medical Center Utrecht (UMCU) within the strategic cancer program. His work bridges computational innovation with clinical molecular medicine.

His research focuses on developing data science methodologies for disease biology, specializing in cancer genomics through nanopore sequencing applications. Key interests include non-invasive diagnostics via liquid biopsies, tumor heterogeneity analysis, and pathogen detection in immunocompromised patients. His lab pioneers tools for oxidative DNA damage quantification and multimodal tumor profiling, translating computational insights into clinical oncology and infectious disease management.

Recent publications reveal a cohesive trajectory in nanopore sequencing applications: 2025 studies emphasize cancer biomarker detection (8-oxo-dG), pediatric fungal diagnostics, and tumor cell-free DNA profiling, while 2024 work extends to neurological contexts including stroke genetics and glioblastoma diagnostics. This demonstrates consistent innovation in adapting sequencing technologies for diverse clinical challenges across oncology, neurology, and infectious diseases.

Complementing his academic role, de Ridder serves as Chief Science Officer at Cyclomics BV, overseeing R&D translation from academic research to biotechnology applications in molecular diagnostics.